Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VISHALA CHINDALORE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1083635015
CMS profile
94470
Location
ANNISTON, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,174.55

208 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,140.97 205
Consulting Fee $2,000.00 1
Education $33.58 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 5 of 5; records 201–208 of 208 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VISHALA CHINDALORE

NPI 1083635015 · CMS profile ID 94470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

ANNISTON, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–208 of 208 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–208 of 208 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–208 of 208 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–208 of 208 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

208 matching records · $5,174.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 208 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–208 of 208.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.9801/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825860813 CMS
AbbVie Inc. $20.8901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794251209 CMS
Amgen Inc. $4.1301/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826452851 CMS
E.R. Squibb & Sons, L.L.C. $16.5701/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783618753 CMS
Cumberland Pharmaceuticals, Inc. $12.4901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854706691 CMS
PFIZER INC. $11.3401/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832689713 CMS
Horizon Therapeutics plc $4.7301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797096519 CMS
PFIZER INC. $20.3501/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832656279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,752.89 194
PY2020 $2,499.64 167
PY2021 $5,174.55 208
PY2022 $3,018.41 174
PY2023 $4,818.68 181
PY2024 $3,714.95 191
PY2025 $3,176.62 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $766.64 1
PY2025 Principal investigator $588,347.88 49
PY2024 Principal investigator $464,278.86 112
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $387,183.21 106
PY2022 Recipient $24,632.48 2
PY2022 Principal investigator $596,933.64 42
PY2021 Principal investigator $189,276.51 71
PY2020 Recipient $300.00 1
PY2020 Principal investigator $496,910.27 53
PY2019 Recipient $6,865.46 1
PY2019 Principal investigator $728,546.57 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Daiichi Sankyo Company LTD $3,314.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1186252419
Principal investigator 1 Daiichi Sankyo Inc. $260.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376205
Principal investigator 1 Daiichi Sankyo Inc. $526.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376219
Principal investigator 1 Daiichi Sankyo Inc. $1,278.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376227
Principal investigator 1 Daiichi Sankyo Inc. $1,250.00 11/07/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376233
Principal investigator 1 GlaxoSmithKline, LLC. $14,064.30 11/05/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120719
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,109.71 10/31/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190306177
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,600.00 10/15/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
An Open label Phase I Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AZD5492 Following Single ascending Dose and Step up Dose Administration to Adult Participants with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies No dispute reported 06/30/2026 1185545051
Principal investigator 1 Hoffmann-La Roche Limited $479.00 10/14/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638629
Principal investigator 1 Hoffmann-La Roche Limited $546.00 10/14/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638633
Principal investigator 1 Hoffmann-La Roche Limited $10,343.15 10/14/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638638
Principal investigator 1 Hoffmann-La Roche Limited $4,709.00 10/14/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638643
Principal investigator 1 GlaxoSmithKline, LLC. $11,097.90 10/02/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120230
Principal investigator 1 Daiichi Sankyo Inc. $0.31 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376195
Principal investigator 1 Daiichi Sankyo Inc. $1.86 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376197
Principal investigator 1 Daiichi Sankyo Inc. $1.36 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376199
Principal investigator 1 Daiichi Sankyo Inc. $0.93 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376201
Principal investigator 1 Daiichi Sankyo Inc. $0.34 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376203
Principal investigator 1 Daiichi Sankyo Inc. $1.86 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376207
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376209
Principal investigator 1 Daiichi Sankyo Inc. $2.04 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376211
Principal investigator 1 Daiichi Sankyo Inc. $2.04 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376213
Principal investigator 1 Daiichi Sankyo Inc. $2.04 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376215
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376217
Principal investigator 1 Daiichi Sankyo Inc. $1.70 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376221
Principal investigator 1 Daiichi Sankyo Inc. $0.68 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376223
Principal investigator 1 Daiichi Sankyo Inc. $2.04 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376225
Principal investigator 1 Daiichi Sankyo Inc. $0.62 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376229
Principal investigator 1 Daiichi Sankyo Inc. $1.36 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376231
Principal investigator 1 Daiichi Sankyo Inc. $1.86 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376235
Principal investigator 1 Daiichi Sankyo Inc. $1.55 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376237
Principal investigator 1 Daiichi Sankyo Inc. $1.02 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376239
Principal investigator 1 Daiichi Sankyo Inc. $1.86 10/01/2025 Non-covered Recipient Entity
Pinnacle Research Group LLC
DS7011-107 No dispute reported 06/30/2026 1223376241
Principal investigator 1 GlaxoSmithKline, LLC. $13,050.90 09/03/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120217
Principal investigator 1 Hoffmann-La Roche Limited $38,996.00 08/21/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638612
Principal investigator 1 GlaxoSmithKline, LLC. $11,403.90 08/01/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120249
Principal investigator 1 GlaxoSmithKline, LLC. $3,318.30 07/02/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120726
Principal investigator 1 Hoffmann-La Roche Limited $6,925.00 06/12/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211638608
Principal investigator 1 GlaxoSmithKline, LLC. $15,314.40 06/04/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120236
Principal investigator 1 GlaxoSmithKline, LLC. $13,608.00 05/09/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120241
Principal investigator 1 GlaxoSmithKline, LLC. $12,049.20 04/02/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120713
Recipient F. Hoffmann-La Roche AG $766.64 03/31/2025 Covered Recipient Physician PhI SAD study of MOSUN in patients with SLE No dispute reported 06/30/2026 1211539477
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,551.62 03/25/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus No dispute reported 06/30/2026 1214125424
Principal investigator 1 GlaxoSmithKline, LLC. $20,293.20 03/07/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120212
Principal investigator 1 GlaxoSmithKline, LLC. $9,382.50 02/05/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120223
Principal investigator 1 Novartis Pharmaceuticals Corporation $62,476.00 01/28/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190299306
Principal investigator 1 Novartis Pharmaceuticals Corporation $191,443.43 01/27/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190299310
Principal investigator 1 ABBVIE INC. $510.00 01/14/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202438216
Principal investigator 1 Novartis Pharmaceuticals Corporation $117,915.32 01/09/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190299301
Principal investigator 1 GlaxoSmithKline, LLC. $7,505.10 01/08/2025 Non-covered Recipient Entity
PINNACLE RESEARCH GROUP
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192120708